1-4 of 4
Bishal Gyawali
Close
Sort by
Journal Articles

High Prevalence of Subjective Minimizing Language in Clinical Trials of Hematologic Malignancies: Natural Language Processing (NLP) Validation Study and Systematic Review of Randomized Controlled Trials Presented at ASH 2009-2021

Benjamin Chin-Yee, Tiancheng Hu, Clarissa Skorupski, Sarah Ghnaim, Bishal Gyawali, Turab Mohammed, James Yu, Gary H. Lyman, Michelle Sholzberg, Lisa Hicks, Nicole M. Kuderer
Journal: Blood
Blood (2023) 142 (Supplement 1): 3709.
https://doi.org/10.1182/blood-2023-180132
Published: 2023
Journal Articles

Toxicity Reporting Is Inconsistent and Incomplete, and Subjective Minimizing Language Is Common in Acute Leukemia Clinical Trials: A Systematic Review of Randomized Controlled Trials Presented at ASH between 2017-2021

Benjamin Chin-Yee, Turab Mohammed, Clarissa Skorupski, Bishal Gyawali, Gary H. Lyman, Lisa K. Hicks, Dr. Nicole M.M. Kuderer
Journal: Blood
Blood (2022) 140 (Supplement 1): 317–318.
https://doi.org/10.1182/blood-2022-157860
Published: 2022
Journal Articles

Inconsistent Adverse Event Reporting: A Systematic Review of Phase 3 Lymphoma or Myeloma Trials Presented at ASH Annual Meetings between 2017-2021

Clarissa Skorupski, Turab Mohammed, Benjamin Chin-Yee, Bishal Gyawali, Gary H. Lyman, Nicole M. Kuderer, Lisa K. Hicks
Journal: Blood
Blood (2022) 140 (Supplement 1): 5060–5061.
https://doi.org/10.1182/blood-2022-162981
Published: 2022
Journal Articles

Incremental Financial and Health-Related Burden of Novel Drugs Used in the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM): A Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)

Binod Dhakal, MBBS, Ravi Narra, MD, Timothy Smunt, MBA, Angela Canadeo, Pharm D, Saurabh Chhabra, MD, Anita d'Souza, MBBS, MD, Bishal Gyawali, MD PhD, Parameswaran Hari, MD MRCP, MS, Saroj Niraula, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3403.
https://doi.org/10.1182/blood.V130.Suppl_1.3403.3403
Published: 2017